Stock analysts at StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH – Get Free Report) in a research note issued to investors on Friday. The brokerage set a “sell” rating on the stock.
Bio-Path Stock Performance
BPTH stock opened at $1.15 on Friday. Bio-Path has a 52-week low of $0.59 and a 52-week high of $12.00. The stock’s 50 day moving average is $0.90 and its two-hundred day moving average is $1.22.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC bought a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path as of its most recent SEC filing. Institutional investors own 5.74% of the company’s stock.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Read More
- Five stocks we like better than Bio-Path
- What is the Dogs of the Dow Strategy? Overview and Examples
- 3 Legacy Tech Companies Reemerging as AI Leaders
- What is an Earnings Surprise?
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- Why Are Stock Sectors Important to Successful Investing?
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
